Document Detail


Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy.
MedLine Citation:
PMID:  21566667     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant in autologous cell-based anti-tumor immunotherapy has recently been approved for clinical application. To avoid the need for individualized processing of autologous cells, we developed a novel strategy based on the encapsulation of GM-CSF-secreting human allogeneic cells. GM-CSF-producing K562 cells showed high, stable and reproducible cytokine secretion when enclosed into macrocapsules. For clinical development, the cryopreservation of these devices is critical. Thawing of capsules frozen at different time points displayed differences in GM-CSF release shortly after thawing. However, similar secretion values to those of non-frozen control capsules were obtained 8 days after thawing at a rate of >1000 ng GM-CSF per capsule every 24 h. For future human application, longer and reinforced capsules were designed. After irradiation and cryopreservation, these capsules produced >300 ng GM-CSF per capsule every 24 h 1 week after thawing. The in vivo implantation of encapsulated K562 cells was evaluated in mice and showed preserved cell survival. Finally, as a proof of principle of biological activity, capsules containing B16-GM-CSF allogeneic cells implanted in mice induced a prompt inflammatory reaction. The ability to reliably achieve high adjuvant release using a standardized procedure may lead to a new clinical application of GM-CSF in cell-based cancer immunization.Cancer Gene Therapy advance online publication, 13 May 2011; doi:10.1038/cgt.2011.22.
Authors:
F Schwenter; S Zarei; P Luy; V Padrun; N Bouche; J S Lee; R C Mulligan; P Morel; N Mach
Related Documents :
3722477 - The tissue distribution of spontaneous cell-mediated cytotoxicity effector lymphocytes ...
16787357 - Sensitization of multidrug resistant (mdr) cancer cells to vinblastine by novel acridon...
16718737 - Cytotoxicity in vitro of naphthazarin derivatives from onosma arenaria.
17137747 - Struggles for equivalence: in vitro developmental toxicity model evolution in pharmaceu...
22474327 - Interaction of notch signaling modulator numb with α-adaptin regulates endocytosis of n...
24635177 - Knocking out smad3 favors allogeneic mouse fetal skin development in adult wounds.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-13
Journal Detail:
Title:  Cancer gene therapy     Volume:  -     ISSN:  1476-5500     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1] Department of Oncology, Geneva University Hospital and Medical School, Geneva, Switzerland [2] Department of Visceral and Transplantation Surgery, Geneva University Hospital and Medical School, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Keratinocyte-specific ablation of the NF-?B regulatory protein A20 (TNFAIP3) reveals a role in the c...
Next Document:  The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gen...